Clinical Applications of a Peptide-Based Vaccine for Glioblastoma

Charles W. Kanaly, Dale Ding, Amy B. Heimberger, John H. Sampson

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.

Original languageEnglish (US)
Pages (from-to)95-109
Number of pages15
JournalNeurosurgery clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Jan 2010

Keywords

  • Brain neoplasms
  • Epidermal growth factor receptor
  • Glioblastoma
  • Immune system
  • Immunotherapy
  • Neoplasm antigens

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Clinical Applications of a Peptide-Based Vaccine for Glioblastoma'. Together they form a unique fingerprint.

Cite this